Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 276.00
Bid: 271.00
Ask: 276.00
Change: -1.00 (-0.36%)
Spread: 5.00 (1.845%)
Open: 277.00
High: 280.00
Low: 274.00
Prev. Close: 277.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DIRECTOR DEALINGS SUMMARY: Nostrum Chairman Sells 18.7 Million Shares

Thu, 02nd Apr 2015 14:02

Director Dealings Summary - Week Ended April 2        
Company Name Position Number of Shares Resulting Holding *Note GBP Value
             
BUYS            
RM2 International John Walsh CEO 1.2 million 22.2 million   648,000
London Capital Group Charles-Henri Sabet CEO 125,000 6.9 million   340,000
Hutchison China Simon To Chairman 18,000 69,000 Same day as concept trial for cancer treatment met efficacy target. 234,000
Hutchison China Edith Shih Non-Executive 18,000 48,000 Same day as concept trial for cancer treatment met efficacy target. 234,000
Standard Life UK Smaller Co's Allister Langlands  Director 50,000 95,000   145,000
Koovs Waheed Alli  Chairman 152,500 4.9 million Same day as Koovs said it would spend more on marketing than anticapted. 99,000
Walker Crips Sean Kin Wai Lam MD 221,000 422,996   95,000
Walker Crips Lim Hua Min Non-Executive 221,000 9.1 million   95,000
Monitise Elizabth Buse CEO 500,000 1 million One week after Monitise said it was no longer for sale  deciding to remain an independent company. 66,000
Stanley Gibbons Martin Bralsford Chairman 22,000 204,800 Same day as profit warning. 52,000
Diploma Andrew Smith Non-Executive 5,500 Undisclosed   45,000
Indivior Shaun Thaxter CEO 20,000 500,000   39,000
Monitise Tim Wade Non-Executive 250,000 350,000 One week after Monitise said it was no longer for sale  deciding to remain an independent company. 35,000
7digital Donald Cruickshank Chairman 140,000 290,000   24,000
Synectics David Coghlan Chairman 20,000 1.5 million   23,000
Plant Impact John Brubaker CEO 40,000 646,000   21,000
Mission Marketing David Morgan Chairman 40,000 6.1 million   17,000
PuriCore Charles Spicer Chairman 50,610 75,000   16,000
Inspirit Energy John Gunn CEO 2 million 355 million Same day as Inspirit said it will deliver its first micro-combined heat and power boiler to a major utility. 13,000
Barclays John McFarlane Incoming Chairman 5,000 6,015 Will become chairman at AGM on April 23. 12,000
LPA Goup Per Staehr Non-Executive 15,000 185,500   11,000
Progility Hugh Crawley CFO 200,000 200,000 Appointed last Friday. 11,000
superGroup Euan Sutherland CEO 10,117 11,613   9,900
Lavendon John Coghlan Non-Executive 5,000 5,500   9600
Aeorema Communications Michael Hale Chairman 25,000 1.7 million   6,900
Churchill China David Taylor CFO 1,000 21,000   6,000
SOCO International Anthony Maris COO 1,213 132,956   1,900
             
             
SELLS            
Nostrum Oil & Gas Frank Monstrey Chairman 18.7 million 32.5 million 2 days after Nostrum reported profit drop. 109,000,000
NAHL Group Samantha Porteous Non-Executive Director 3.1 million Nil 3 days after NAHL reported profit drop in maiden results. 7,600,000
IHG Tracy Robbins Director 28,047 183,997   738,000
Michael Page Oliver Watson Director 101,620 Undisclosed   540,000
Jupiter Fund Management Adrian Creedy Company Secretary 100,000 1.8 million   414,000
STV Group Rob Woodward CEO 100,000 419,322   383,000
Nichols Peter Nichols Chairman 17,060 2.1 million   201,000
Tribal Group Steve Breach Finance Director 81,296 172,728 2 weeks after Tribal swung to a loss. 120,000
Witan Investment Trust Harry Henderson Chairman 2,100 722,732   17,000
             
*Note: A recent company event around the time of the dealing does not suggest the dealing took place because of that event. When a spouse or related party to a director buys shares, the resulting holding is the beneficial holding of the director
 
             
Contact: +44 207 199 0340; newsroom@alliancenews.com; @AllNewsTeam      
             
Copyright 2015 Alliance News Limited. All Rights Reserved.        

More News
20 Jan 2022 11:03

Hutchmed begins phase one study for potential tumour treatment

Hutchmed begins phase one study for potential tumour treatment

Read more
13 Jan 2022 09:10

TOP NEWS: Retailer ASOS now to be seen on London Main Market

TOP NEWS: Retailer ASOS now to be seen on London Main Market

Read more
12 Jan 2022 11:37

Hutchmed gains breakthrough therapy designation in China for HMPL-523

Hutchmed gains breakthrough therapy designation in China for HMPL-523

Read more
10 Jan 2022 09:23

Hutchmed begins phase one study for potential cancer treatment

Hutchmed begins phase one study for potential cancer treatment

Read more
6 Dec 2021 10:44

Hutchmed completes patient enrolment for cancer drug study

Hutchmed completes patient enrolment for cancer drug study

Read more
3 Dec 2021 13:23

Two Hutchmed drugs included in China's 2022 reimbursement list

(Sharecast News) - Hutchmed China announced on Friday that, following negotiations with the China National Healthcare Security Administration (NHSA), from 1 January the updated National Reimbursement Drug List (NRDL) will continue to include 'Elunate', or fruquintinib, and would now include 'Sulanda', or surufatinib.

Read more
3 Dec 2021 09:54

Two Hutchmed drugs included on China's state approved medicines list

Two Hutchmed drugs included on China's state approved medicines list

Read more
24 Nov 2021 11:35

Hutchmed China shares rise on Orphathys and Tagrisso Phase 3 study

Hutchmed China shares rise on Orphathys and Tagrisso Phase 3 study

Read more
1 Nov 2021 09:14

TOP NEWS: Astra transfers drug rights to Covis in USD270 million deal

TOP NEWS: Astra transfers drug rights to Covis in USD270 million deal

Read more
28 Oct 2021 21:59

IN BRIEF: Hutchmed begins phase 3 trial of thrombocytopenia drug

IN BRIEF: Hutchmed begins phase 3 trial of thrombocytopenia drug

Read more
29 Sep 2021 11:08

Hutchmed China sells joint venture stake for USD169 million

Hutchmed China sells joint venture stake for USD169 million

Read more
21 Sep 2021 10:51

Hutchmed starts drug combination trial for neuroendocrine tumours

Hutchmed starts drug combination trial for neuroendocrine tumours

Read more
20 Sep 2021 09:09

Hutchmed starts Japan trial for surufatinib in neuroendocrine tumors

Hutchmed starts Japan trial for surufatinib in neuroendocrine tumors

Read more
13 Sep 2021 10:22

Hutchmed China's amdizalisib secures breakthrough therapy designation

Hutchmed China's amdizalisib secures breakthrough therapy designation

Read more
8 Sep 2021 13:49

Hutchmed, Astra launch drug combination trial to treat lung cancer

Hutchmed, Astra launch drug combination trial to treat lung cancer

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.